<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF9032CD-D00B-46E7-A542-060711A08276"><gtr:id>BF9032CD-D00B-46E7-A542-060711A08276</gtr:id><gtr:name>Advent Life Science</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/92463A51-1BA5-4C6D-8C6D-75B996471C33"><gtr:id>92463A51-1BA5-4C6D-8C6D-75B996471C33</gtr:id><gtr:name>Government of Thailand</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0B638AA-F9B3-48E6-A841-17B44A6152C9"><gtr:id>C0B638AA-F9B3-48E6-A841-17B44A6152C9</gtr:id><gtr:name>University of Portsmouth</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF9032CD-D00B-46E7-A542-060711A08276"><gtr:id>BF9032CD-D00B-46E7-A542-060711A08276</gtr:id><gtr:name>Advent Life Science</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92463A51-1BA5-4C6D-8C6D-75B996471C33"><gtr:id>92463A51-1BA5-4C6D-8C6D-75B996471C33</gtr:id><gtr:name>Government of Thailand</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0B638AA-F9B3-48E6-A841-17B44A6152C9"><gtr:id>C0B638AA-F9B3-48E6-A841-17B44A6152C9</gtr:id><gtr:name>University of Portsmouth</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F0ABC82D-487A-47F3-A0EE-F950EF783AD6"><gtr:id>F0ABC82D-487A-47F3-A0EE-F950EF783AD6</gtr:id><gtr:firstName>Amin</gtr:firstName><gtr:surname>Hajitou</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701159"><gtr:id>55A6C1A6-E64D-4045-9A70-D8F0D7723144</gtr:id><gtr:title>Hybrid prokaryotic-eukaryotic vectors for targeted gene delivery to brain tumours in animal models</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701159</gtr:grantReference><gtr:abstractText>We aim to develop a novel strategy for the treatment of human glioblastomas. These brain tumours are one of the most lethal malignancies. Despite progress in neurosurgery, radiation and chemotherapy, little progress has been made in the treatment of these tumours. Therefore, new therapeutic strategies are urgently needed.

Gene therapy is an attractive approach for cancer treatment. Glioblastomas were one of the earliest targets of cancer gene therapy, but the first clinical trials were not successful because of the inefficient delivery of therapeutic genes into the tumours. Thus, there is a need to develop new vector systems that are safe and able to provide strong expression of the therapeutic genes within the tumours. To achieve these two goals, these vectors need to be specifically targeted to the tumour tissue.

We have recently showed that combination of attributes of various viruses resulted in the generation of hybrid viral vectors for efficient and targeted systemic gene therapy. We will use this strategy to generate a novel hybrid vector for targeted delivery of therapeutic genes to glioblastoma.

These approaches could result in the derivation of a targeted vector system which would represent a major advance in the management and therapy of human glioblastoma.</gtr:abstractText><gtr:technicalSummary>Human malignant gliomas are highly-aggressive central nervous system tumors. The effect of current therapies is limited, and novel therapeutic approaches are required to improve the treatment of brain tumors. Gene therapy has shown early promise and presents an interesting approach for intervention; however, in brain tumor patients, efficacy has been hindered by low tumor transduction rates.
We have reported (Hajitou et al. Cell 2006) the generation of targeted hybrid prokaryotic-eukaryotic vectors, which are chimeras between two single-stranded DNA viruses, an adeno-associated virus (AAV) and targeted bacteriophage (termed AAV phage; AAVP). In our prototype, the AAV transgene cassette is inserted in an intergenomic region of the bacteriophage (phage) genome and is packaged with the phage DNA into the capsid. In addition, the vector displays the RGD 4C ligand on the phage capsid to specifically target alpha v integrin receptors overexpressed in many tumors. The combination showed improved systemic delivery and transduction for imaging and therapy. 
In this application, we propose to develop a new chimeric phage-based vector for targeted delivery of therapeutic/imaging genes to angiogenic vasculature and tumor cells in brain tumors. Specifically, we will increase vector transport through the blood-brain barrier by displaying on the bacteriophage capsid ligands for transcytosis such as transferrin. Moreover, we will combine attributes of prokaryotic and eukaryotic viruses to improve endosomal escape so as to achieve superior tumor transduction. Thus, these approaches could result in the derivation of an improved targeted vector system which would represent a major advance in the management of brain tumors and the development of gene therapy systems for patient use.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>436216</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Targeted T-cell activation by tumour-associated neo-vasculature</gtr:description><gtr:id>0F8BD886-6201-4CAC-9506-BF5A83B7D7A3</gtr:id><gtr:impact>We are in the process of generating preliminary data to demonstrate the feasibility of combining our technology with that of our collaborator. This will allow us to apply for funding in order to pursue this very promising combination of the two technologies.</gtr:impact><gtr:outcomeId>GRP5T8APJLa-1</gtr:outcomeId><gtr:partnerContribution>My collaborator has provide research material needed to initiate the project.</gtr:partnerContribution><gtr:piContribution>On our side we provide the vascular-targeted bacteriophage vector in order to express on the surface of tumour blood vessels the necessary ligands that guide T-lymphocytes to the tumour vasculature for a targeted cancer immunotherapy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemical Engineering</gtr:department><gtr:description>Phage/polymer hybrid nanomaterials</gtr:description><gtr:id>CB95CDAD-A073-478C-9B65-34AD3D58EA41</gtr:id><gtr:impact>1- The work has been published in Moelcualr Therapy- Nucleic Acids, 2014.

Title: Hybrid nanomaterial complexes for advanced phage-guided gene delivery

Authors: Teerapong Yata, Koon-Yang Lee, Tararaj Dharakul, Sirirurg Songsivilai, Alexander Bismarck, Paul Mintz and Amin Hajitou.

2- A patent application was also filed by Imperial Innovations.</gtr:impact><gtr:outcomeId>h7j2YPCA8gk-1</gtr:outcomeId><gtr:partnerContribution>Our partners carried out an extensive physicochemical characterisation of the new phage/polymer hybrid nanomaterials.</gtr:partnerContribution><gtr:piContribution>My PhD student designed hybrids of targeted bacteriophage and cationic polymers, and subsequently converted the negative charge of bacteriophage into a positively charged surface. Then he showed that the new positively-charged phage capsid acquired strong attachment to the negatively charged membranes of cancer cells, resulting in dramatic increase of gene delivery and targeted tumour cell killing by bacteriophage.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Phage-guided expression of human factor IX (FIX) for the treatment of haemophilia B.</gtr:description><gtr:id>FD93CAB5-C55D-4C83-A8D0-677EBAE67BAA</gtr:id><gtr:impact>Strong collaboration with University College London, and proof of efficacy of phage gene therapy for diseases other than cancer.</gtr:impact><gtr:outcomeId>CBMX7EkjVt6-1</gtr:outcomeId><gtr:partnerContribution>Provide the human factor IX transgene.</gtr:partnerContribution><gtr:piContribution>We have generated a ligand-targeted bacteriophage vector for expression of the human factor IX in the liver, after intravenous administration, and its subsequent release into the blood circulation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Design and generation of novel M13 filamentous bacteriophage vectors with double-stranded DNA.</gtr:description><gtr:id>0B6A1263-E613-486A-BCDA-E4723E0D5023</gtr:id><gtr:impact>A patent application is being prepared.</gtr:impact><gtr:outcomeId>LwAt64cUVPc-1</gtr:outcomeId><gtr:partnerContribution>Our partners will aim to establish that this enhanced gene delivery by bacteriophage, in glioblastoma cells, is the result of efficient conversion to double-stranded DNA. They will also provide us with self-complementary AAV transgene cassettes to insert into our bacteriophage vector in order to generate double stranded-DNA in transduced cells and subsequently increase gene expression by bacteriophage in cancer cells.</gtr:partnerContribution><gtr:piContribution>We have used a panel of drugs, such as Genestein, known for their ability to convert single-stranded to double-stranded DNA, and showed that they have the ability to increase gene transfer efficacy to gliobalstoma cells by our single-stranded bacteriophage vector.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Thailand</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>Use of bacteriophage as a delivery system in DNA vaccine applications.</gtr:description><gtr:id>9A34F13F-875A-4718-A26E-712B8B9FC13F</gtr:id><gtr:impact>This collaboration has just started</gtr:impact><gtr:outcomeId>54591e0d185d74.14696464-1</gtr:outcomeId><gtr:partnerContribution>The government of Thailand will fund a Thai PhD student who will work on the project and study the PhD under my supervision at Imperial College London.</gtr:partnerContribution><gtr:piContribution>We will supervise in my lab a PhD student funded by the Government of Thailand.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Targeted Gene Therapy of Lymphoma</gtr:description><gtr:id>ED7E001E-6D77-4A27-A548-379590E43E9C</gtr:id><gtr:impact>The work should result in future Publications and funding</gtr:impact><gtr:outcomeId>3C3FCE0FB7A-1</gtr:outcomeId><gtr:partnerContribution>They provide the in vivo models of human lymphoma in mice.</gtr:partnerContribution><gtr:piContribution>My team has generated vectors for use in targeted gene therapy of lymphoma models in mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ligand-directed phage for gene transfer to uterine smooth muscle cells.</gtr:description><gtr:id>C41750D9-E24D-455C-9FDE-4B5E0361F2B1</gtr:id><gtr:impact>A collaboration, funding and future applications for larger funding.</gtr:impact><gtr:outcomeId>L9cUTa7CAax-1</gtr:outcomeId><gtr:partnerContribution>They provide the human uterine smooth muscle cells.</gtr:partnerContribution><gtr:piContribution>We have constructed a phage vector displaying the ocytocin ligand for gene transfer to uterine smooth muscle cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Clinical Translation</gtr:department><gtr:description>Targeted combination therapy of intracranial human glial tumours in mice.</gtr:description><gtr:id>4B7EC446-83CA-415C-B076-1D8E140F2EF0</gtr:id><gtr:impact>We have published a collaborative paper:

Przystal, J.M., Umukoro, E., Stoneham, C.A., Yata, T., O'Neill, K., Syed, N. and Hajitou A. &amp;quot;Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage&amp;quot; Mol. Oncol. (2012) Aug 21. [Epub ahead of print].</gtr:impact><gtr:outcomeId>fo5hw2fuRCA-1</gtr:outcomeId><gtr:partnerContribution>To grow human glioblastoma cells from cancer patients and provide them to us for implantation in mice.</gtr:partnerContribution><gtr:piContribution>To grow human glioblastoma from cancer patients in the brain of mice and assess the effects of targeted gene therapy in combination with other therapies e.g. chemotherapy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Experimental Medicine</gtr:department><gtr:description>Association of histone modification and DNA methylation status with efficacy of glioblastoma gene therapy by bacteriophage.</gtr:description><gtr:id>0BC3AE4C-D3BE-4B8A-83FF-B01AFA65DCC0</gtr:id><gtr:impact>PMID: 24153059</gtr:impact><gtr:outcomeId>ruCANfDy2Et-1</gtr:outcomeId><gtr:partnerContribution>My partners provided us with inhibitors of histone deacetylation and DNA methylation as well as guidance for the work, given their expertise in the epigenetic field.</gtr:partnerContribution><gtr:piContribution>My research technician, funded by my MRC award, used inhibitors of histone deacetylation and DNA methylation to show that modulation of the histones and DNA methylation status enhance bacteriophage gene therapy against glioblastoma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Jenner Institute</gtr:department><gtr:description>Phage-guided cancer DNA and peptide vaccines</gtr:description><gtr:id>B87FF189-D897-41EC-B3FA-4C34FB3D85C0</gtr:id><gtr:impact>The experimental work has started in October 2015.</gtr:impact><gtr:outcomeId>56dee119262b78.65446863-1</gtr:outcomeId><gtr:partnerContribution>My partners have provided us with the foreign antigens to use. They will also perform in vitro tests in their lab.</gtr:partnerContribution><gtr:piContribution>My team will has constructed tumour targeted bacteriophage vectors for intravenous delivery of foreign antigens to tumours in preclinical models.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Thailand</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>National Science and Technology Development Agency (NSTDA)</gtr:department><gtr:description>Vascular-targeted molecular imaging and therapy of breast cancer</gtr:description><gtr:id>C84E1969-1990-4B86-9670-B64788C89174</gtr:id><gtr:impact>The work is progressing very well and a publication is being submittded..</gtr:impact><gtr:outcomeId>m4WnPFJGLs1-1</gtr:outcomeId><gtr:partnerContribution>Provides a studentship support (tuition fees and living expenses) for a student from Thailand to do the PhD at Imperial College London under my supervision.</gtr:partnerContribution><gtr:piContribution>Our contribution is to use single chain antibodies displayed in the context of bacteriophage capsid in order to systemically target imaging and therapeutic transgenes to the angiogenic vscaulature of breast cancer in mice</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advent Life Science</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:description>Phage-guided CAR T cell immunotherapy against CD19 antigene in cancer</gtr:description><gtr:id>DDBD4A98-8CCF-4CAF-8678-BB22284550E0</gtr:id><gtr:impact>The collaboration is just starting.</gtr:impact><gtr:outcomeId>56e03c1f1c1d35.75318089-1</gtr:outcomeId><gtr:partnerContribution>Our partners will provide CAR T cells displaying an antibody against CD19 on their cell surface.</gtr:partnerContribution><gtr:piContribution>We will construct bacteriophage vectors to deliver CD19 gene expression to tumours in vivo following intravenous administration.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Portsmouth</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy and Biomedical Sciences Portsmouth</gtr:department><gtr:description>Phage therapy against medulloblastoma</gtr:description><gtr:id>1702C482-3848-4F26-BFD5-932EE5566AFC</gtr:id><gtr:impact>Collaboration with the University of Portsmouth.</gtr:impact><gtr:outcomeId>hsM3x2TcUci-1</gtr:outcomeId><gtr:partnerContribution>They provide a panel of human medulloblastoma cell lines.</gtr:partnerContribution><gtr:piContribution>We have generated multifunctional phage particles for the simultaneous targeting of molecular targets in medulloblastoma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>19661</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BCC Small Pilot Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:id>54B45C9D-0A9C-4D3E-A8A8-DD12534BF134</gtr:id><gtr:outcomeId>09DF10F5E7E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76308</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD student support</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Brain Tumour Research Campaign (BTRC)</gtr:fundingOrg><gtr:fundingRef>P47733</gtr:fundingRef><gtr:id>EAE449CF-37B5-4859-9549-C68AA8C89D14</gtr:id><gtr:outcomeId>PH9s6MKC7FU</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Leverhulme Trust Fellowship</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>The Leverhulme Trust</gtr:fundingOrg><gtr:id>4B69E4A9-30C3-43A5-962C-520A1CA2439C</gtr:id><gtr:outcomeId>tBX7WAnrqsG0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant application.</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>982061F9-4E8F-439B-B8A0-F6DC93DC4546</gtr:id><gtr:outcomeId>c4VUxk6SLWV</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant application.</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Brain Tumour Research Campaign (BTRC)</gtr:fundingOrg><gtr:id>061355B3-651C-4740-9F78-9F5230248147</gtr:id><gtr:outcomeId>rTuPyQWhTzr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Supplement Funds</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Brain Tumour Research Campaign (BTRC)</gtr:fundingOrg><gtr:id>FFA5972E-2408-48EE-8783-D9A135D15FED</gtr:id><gtr:outcomeId>5458fa143d3583.41968146</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>333809</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Delivery of therapy to childhood CNS tumours</gtr:description><gtr:end>2021-01-02</gtr:end><gtr:fundingOrg>Children with Cancer UK</gtr:fundingOrg><gtr:id>599F097F-5478-415B-9670-1607D0C599BA</gtr:id><gtr:outcomeId>58c7c8a5a8f7b2.58515606</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2018-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>219854</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant application.</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Children with Cancer UK</gtr:fundingOrg><gtr:fundingRef>2013/147</gtr:fundingRef><gtr:id>5D4EA9E4-3D4F-4832-AFA5-45E9DAE8AEA0</gtr:id><gtr:outcomeId>Ve8szRsQK2M</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept Fund</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Imperial Innovations</gtr:fundingOrg><gtr:fundingRef>6794</gtr:fundingRef><gtr:id>9CCB7D1A-742A-4221-B497-89859EE86292</gtr:id><gtr:outcomeId>5458ca8dd3a359.55116935</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>Thailand, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD student bench fees.</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Government of Thailand</gtr:fundingOrg><gtr:id>438986A3-DDC9-4AD2-942E-E7BA0033DD5C</gtr:id><gtr:outcomeId>noZXWYCHErL</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centenary Award</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B4149553-9770-4F88-B193-39E809B3A889</gtr:id><gtr:outcomeId>W5D2GDikSkd</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.</gtr:description><gtr:grantRef>G0701159</gtr:grantRef><gtr:id>A9322193-AA28-4410-B756-7886BE74674B</gtr:id><gtr:impact>The discovery has attracted further funding and collaborations with Industry.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56dee65a47c341.55609228</gtr:outcomeId><gtr:patentId>WO2014184529</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BACTERIOPHAGE</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.</gtr:description><gtr:grantRef>G0701159</gtr:grantRef><gtr:id>AEE3121B-0998-4E10-BAE3-D58E706D8EF2</gtr:id><gtr:impact>The discovery has attracted further funding, and collaborations with industrial partners.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56dee52cb084f6.93826244</gtr:outcomeId><gtr:patentId>WO2014184528</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BACTERIOPHAGE</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product:
is a multifunctional filamentous phage as a new hybrid between two M13 filamentous phage. The product can be used i) as a carrier for mammalian transgene cassettes inserted in an intergenomic region of the bacteriophage for gene delivery to mammalian cells, ii) as a display system of a tumour targeting ligand, and iii) as a carrier for therapeutic peptides.

Current stage:
The product has been successfully tested in vitro on tumour cell lines. Next we will assess the efficacy of the product in tumour-bearing mice in vivo.

Principle source of funding for this development: Medical Research Council.

An international patent application has been filed by Imperial Innovations.</gtr:description><gtr:id>29B86BC4-B6B2-4F92-9E31-7EE1536709BF</gtr:id><gtr:impact>Wide biotechnological and clinical applications of phage particles and a breakthrough for phage applications in nanomedicine.</gtr:impact><gtr:outcomeId>Ryv1J88XQd8</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Hybrid multifunctional filamentous bacteriophage nanocarrier</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Bacteriophage (phage), viruses that infect bacteria only, have shown promise for targeted gene transfer applications. Unfortunately, only minor progress has been made in improving their potential and enabling them to overcome mammalian cellular barriers. We hypothesized that one of the limitations of phage is its surface negative charge, which could hinder its access to negatively charged eukaryotic cell membranes and subsequent binding to the target cell receptor. Therefore, we generated a novel hybrid system consisting of two classes of nanomaterial systems, cationic polymers and the M13 bacteriophage virus particles genetically engineered to display a tumor targeting ligand and to carry a transgene cassette. We show that complexation of phage with cationic polymers generates positively charged phage which show enhanced cell surface attachment and improved transgene expression while retaining cell type specificity. Moreover, phage/polymer complexes carrying a therapeutic gene achieve greater targeted cancer cell killing than phage alone. 

An international patent application has been filed by Imperial Innovations.</gtr:description><gtr:id>F32812C8-C704-4337-8EE8-3D1081CF5B1E</gtr:id><gtr:impact>This new class of hybrid of phage/polymer nanomaterial platform can advance targeted gene delivery applications in general, and gene transfer by bacteriophage in particular.</gtr:impact><gtr:outcomeId>h1cioXihSfu</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Phage/polymer hybrid nanoparticles</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have designed a multifunctional filamentous bacteriophage (phage) as a new hybrid between two M13 filamentous phage fUSE5 and f88-4. This phage chimera serves i) as a carrier for a mammalian transgene cassette inserted in an intergenomic region of the bacteriophage genome for gene delivery to mammalian cells ii) as a display system of a tumour targeting ligand on the pIII minor coat protein of the fUSE5 phage and iii) as a genetic carrier for foreign functional peptides to be displayed on the pVIII major coat protein of f88-4 phage in order to operate as a nanoparticle (nanotube) decorated by hundreds of anticancer peptides.</gtr:description><gtr:id>A5DF0699-7776-4B6E-BF5C-D861D8605BDF</gtr:id><gtr:impact>The novel multifunctional phage will be applied as vehicle to target cell surface receptors in activated endothelium-derived cells or tumour cells in mouse tumour models. Target specificity will be based on tumour vascular homing ligands displayed on the phage coat. The cargo will be a packaged gene incorporated into the phage genome for gene delivery applications, or imaging agents or cytotoxic peptides displayed at high density onto the phage coat. This strategy is likely to lead to clinical applications of phage in nanomedicine related to therapy and imaging and would represent a major advance in the management of cancer and other human diseases.</gtr:impact><gtr:outcomeId>SPtXBk9kcsg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Multifunctional bacteriophage nanoparticles</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The research reagent is hybrid nanomaterials of bacteriophage (phage) and cationic polymers. These phage/polymer hybrids show substantial increase of targeted gene delivery by bacteriophage, and subsequently dramatic enhancement of bacteriophage gene therapy.</gtr:description><gtr:id>1A137A5F-0782-440A-9AB1-84B0A1A30FE0</gtr:id><gtr:impact>A patent application has been filed by Imperial Innovatiopns.

The hybrid of phage and cationic polymers should have a notable impact on gene transfer by bacteriophage and expand the application of phage in gene transfer technology in several fields, from gene therapy to DNA vaccine delivery, both in academia and industry as well.</gtr:impact><gtr:outcomeId>sn712HmhEoE</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Efficacy of gene therapy by bacteriophage is improved by hybrid phage/polymer nanomaterials.</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3A0EF7F6-8EFD-4316-B0F6-12D088ECD016</gtr:id><gtr:title>Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d1436ca5790cea27cc3182c5340c6b5"><gtr:id>5d1436ca5790cea27cc3182c5340c6b5</gtr:id><gtr:otherNames>Asavarut P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>545cf385dcbcd9.91550506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>410DF4FD-BA11-4266-BBF8-BEE9B324848A</gtr:id><gtr:title>The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7c981b0ea9626b19d00a358a5e07fe5"><gtr:id>b7c981b0ea9626b19d00a358a5e07fe5</gtr:id><gtr:otherNames>Tsafa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>585d6532d50828.18866519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DC89368-AD1E-45FB-9FE8-97304C8193F2</gtr:id><gtr:title>Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f9f9092f5ac4efb6543bce1866e4591"><gtr:id>5f9f9092f5ac4efb6543bce1866e4591</gtr:id><gtr:otherNames>Dobroff AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d57cd1503f2.74570640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B8E476A-42F8-41F0-A74D-30FFC8D1A1A2</gtr:id><gtr:title>A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/993787d87b119db506bf2b33b51a5e5d"><gtr:id>993787d87b119db506bf2b33b51a5e5d</gtr:id><gtr:otherNames>Trepel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>D28A8050D31</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>453A54AF-C5F3-441D-87AE-8604529CC2F5</gtr:id><gtr:title>Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb14e13d3ebe32cc6c0726b293a7f052"><gtr:id>cb14e13d3ebe32cc6c0726b293a7f052</gtr:id><gtr:otherNames>Yata T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>5675e5bc69128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01DBCFF7-E946-4884-9752-EACA30F59CF7</gtr:id><gtr:title>Gene Therapy of Cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5432e9deec926068001ca5e2a74e1a7a"><gtr:id>5432e9deec926068001ca5e2a74e1a7a</gtr:id><gtr:otherNames>Yata Teerapong</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>jCg8nzES5jg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65AACE21-969C-4995-876A-D15C5D3CD400</gtr:id><gtr:title>Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3d3c5e4e57cff727ce8e24e9e20fe64"><gtr:id>f3d3c5e4e57cff727ce8e24e9e20fe64</gtr:id><gtr:otherNames>Stoneham CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_16088_28_22915587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67DBD892-5BA7-4C35-95B1-FEC563154AFC</gtr:id><gtr:title>Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d754f4bea0ad49ec23621d6c06742678"><gtr:id>d754f4bea0ad49ec23621d6c06742678</gtr:id><gtr:otherNames>Kia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_16088_28_24153059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A7E328D-523E-480A-A3F2-92CE405D14AB</gtr:id><gtr:title>Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b08b41fe947e5b64be17f51017f92fe"><gtr:id>0b08b41fe947e5b64be17f51017f92fe</gtr:id><gtr:otherNames>Paoloni MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>top4RtVisrU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66BBE8BA-F3EB-484C-9876-706AE9DB3651</gtr:id><gtr:title>CRISPR/Cas9: Transcending the Reality of Genome Editing.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c293acf818b2362e27625227586f0ef"><gtr:id>7c293acf818b2362e27625227586f0ef</gtr:id><gtr:otherNames>Chira S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa58ceccfbb50.15416523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75C2D7D-E7F1-4D95-9E5C-74AC87D0B2F2</gtr:id><gtr:title>Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb14e13d3ebe32cc6c0726b293a7f052"><gtr:id>cb14e13d3ebe32cc6c0726b293a7f052</gtr:id><gtr:otherNames>Yata T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5458c30ee838d9.48831742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9456511C-CDF2-48DA-99F7-118E72473587</gtr:id><gtr:title>Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76422c32d7ee32a1eb4e4bf739f1dc5b"><gtr:id>76422c32d7ee32a1eb4e4bf739f1dc5b</gtr:id><gtr:otherNames>Donnelly A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>56dedea9a83808.79655046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>278F12CB-CF8D-4528-B3BA-8D1D315511A5</gtr:id><gtr:title>Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9fa2c4ed0cf5d9dd639ab173d60a520"><gtr:id>f9fa2c4ed0cf5d9dd639ab173d60a520</gtr:id><gtr:otherNames>Przystal JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>pm_16088_28_22951279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52C7CAE3-0A88-4728-870A-115DE8EDF1CC</gtr:id><gtr:title>Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/636a5dd9c5af577229493f55bd4ad482"><gtr:id>636a5dd9c5af577229493f55bd4ad482</gtr:id><gtr:otherNames>Mitchell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>SazuPVjUXaR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BCC615-82D0-4DE7-BA6D-B74EE0891DB9</gtr:id><gtr:title>A perspective on non-catalytic Src homology (SH) adaptor signalling proteins.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03aad1262b0a0bc3af0047af2d714c81"><gtr:id>03aad1262b0a0bc3af0047af2d714c81</gtr:id><gtr:otherNames>Reebye V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>dYXvS1cYs9x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60A257E5-D881-4C89-B6F1-149061E1EDE5</gtr:id><gtr:title>Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc1556a59502f518c0c50f1907e32f66"><gtr:id>fc1556a59502f518c0c50f1907e32f66</gtr:id><gtr:otherNames>Tandle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>iwJJ3zgn1Yp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF3AC9CC-5022-4C75-953E-4E287D64C987</gtr:id><gtr:title>Bacteriophage-derived vectors for targeted cancer gene therapy.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6cf4b3a525e15293fa7945b74a15d7b"><gtr:id>c6cf4b3a525e15293fa7945b74a15d7b</gtr:id><gtr:otherNames>Pranjol MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>doi_55faa1aa1d29645c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9796272-56AD-4049-A9A5-A79A303EAE13</gtr:id><gtr:title>A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/558c845d316f81c6a64a318d8963f12a"><gtr:id>558c845d316f81c6a64a318d8963f12a</gtr:id><gtr:otherNames>Hajitou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>jf5vLXmSBAW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55E95454-7776-41E0-B1E0-05D47E198D86</gtr:id><gtr:title>Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.</gtr:title><gtr:parentPublicationTitle>Advances in genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/558c845d316f81c6a64a318d8963f12a"><gtr:id>558c845d316f81c6a64a318d8963f12a</gtr:id><gtr:otherNames>Hajitou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0065-2660</gtr:issn><gtr:outcomeId>kJpp84vDbqs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12C2D5B-463B-4FE6-A424-8EC2F70680F1</gtr:id><gtr:title>Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d754f4bea0ad49ec23621d6c06742678"><gtr:id>d754f4bea0ad49ec23621d6c06742678</gtr:id><gtr:otherNames>Kia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>pm_16088_28_23053496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F50AAF53-65AB-49AA-B53F-B92DDC2E7A9D</gtr:id><gtr:title>The phage revolution against antibiotic resistance</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d1436ca5790cea27cc3182c5340c6b5"><gtr:id>5d1436ca5790cea27cc3182c5340c6b5</gtr:id><gtr:otherNames>Asavarut P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5458c68cd26269.87998245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70601193-8510-43F3-848C-CF7F2398F078</gtr:id><gtr:title>An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/021dba52c3c7cae148e9c3ea842a50c0"><gtr:id>021dba52c3c7cae148e9c3ea842a50c0</gtr:id><gtr:otherNames>Mintz PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Ht99FiHwMo7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55915CD9-AFBB-477E-A3B3-70A44BB2BC1E</gtr:id><gtr:title>Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03aad1262b0a0bc3af0047af2d714c81"><gtr:id>03aad1262b0a0bc3af0047af2d714c81</gtr:id><gtr:otherNames>Reebye V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>qha8jMqQvoM</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701159</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>